Login | Register

FDA Grants Priority Review For The Hepatitis C Drug “Sofosbuvir”

The U.S. Food and Drug Adminstration (FDA) has just granted priority review to Gilead Sciences Inc.'s latest New Drug Application (NDA) for "Sofosbuvir", an experimental drug candidate for the treatment of hepatitis C. On April 8, 2013 the company filed the NDA for review and the FDA has determined a target review date under the Prescription Drug User Fee Act of December 8...

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *